New drug cocktail aims to boost immune attack on lung cancer

NCT ID NCT07507188

Not yet recruiting Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests two drug combinations for people with a specific genetic mutation (EGFR) in advanced non-small cell lung cancer. One group receives amivantamab plus lazertinib as first treatment; the other gets amivantamab plus chemotherapy after previous treatment stopped working. The study looks at how these drugs change the tumor's immune environment and whether they shrink tumors. About 60 adults will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: amivantamab plus lazertinib or amivantamab plus chemotherapy (carboplatin and pemetrexed)
What this could lead to: If successful, this could point toward more effective treatment combinations for EGFR-mutant lung cancer, potentially improving tumor shrinkage and delaying progression.
What could go wrong: This is an early Phase 2 study with only 60 participants, so results may not apply to all patients. The primary goal is to study immune changes, not to prove clinical benefit yet.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.